QED Therapeutics, a BridgeBio Company
Clinical trials sponsored by QED Therapeutics, a BridgeBio Company, explained in plain language.
A biotech subsidiary of BridgeBio developing targeted therapies for genetic diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New study tracks growth in kids with rare bone disorder Results expected Oct 2026 (estimated) May already have reported ↗
- Could a daily pill boost growth in kids with hypochondroplasia? Results expected Jan 2027 (estimated) May already have reported ↗
-
New pill could help kids with dwarfism grow better
Disease control Recruiting nowThis study tests an oral drug called infigratinib in infants and children under 3 years old with achondroplasia, the most common form of dwarfism. The goal is to see if it safely improves growth and body proportions. The trial has several phases to find the right dose and then co…
Phase 2 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New study tracks growth in kids with rare bone disorder
Knowledge-focused Recruiting nowThis study watches children aged 2.5 to 17 with hypochondroplasia, a condition causing short stature, to track their growth and health over time. No treatments or drugs are given. The goal is to learn more about how the condition affects growth, body proportions, thinking skills,…
Sponsor: QED Therapeutics, a BridgeBio company • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC